Copyright
©The Author(s) 2017.
World J Hepatol. Jun 18, 2017; 9(17): 791-796
Published online Jun 18, 2017. doi: 10.4254/wjh.v9.i17.791
Published online Jun 18, 2017. doi: 10.4254/wjh.v9.i17.791
Table 1 Baseline characteristics of the 133 patients
| Characteristic | Value |
| Gender | 97M/36F |
| Age (yr) | 47.5 ± 11.3 |
| Indication for FibroScan | |
| HCV | 79 |
| HBV | 54 |
| Mean FibroScan score (kPa) | 11.5 |
| Mean IQR (kPa) | 2.17 |
| Mean success rate | 95.6% |
| Mean APRI score | 0.75 |
| Mean AST level (U/L) | 65.5 |
| Mean platelet count (× 109/L) | 214 |
Table 2 Performance indicators of aspartate aminotransferase to platelet ratio score 1.0 and FibroScan for advanced fibrosis
| APRI | FibroScan | |
| Sensitivity | 51.9% | 63.0% |
| Specificity | 84.9% | 84.0% |
| PPV | 46.7% | 50.0% |
| NPV | 87.4% | 89.9% |
| Accuracy | 78.2% | 79.7% |
- Citation: Wong S, Huynh D, Zhang F, Nguyen NQ. Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis. World J Hepatol 2017; 9(17): 791-796
- URL: https://www.wjgnet.com/1948-5182/full/v9/i17/791.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i17.791
